Prior to joining NorthX, Hoogstraate was CEO of Valneva Sweden. She succeeds Helena Strigård. She will act as an advisor to Janet Hoogstraate in this crucial phase before she takes on a new leadership role in another company.

Dr Janet Hoogstraate holds a PhD in biopharmaceutical sciences from Leiden University in the Netherlands. She has conducted research at the University of Utah and the University of Iowa, USA, and has worked in the pharmaceutical industry since 1995 in research and all phases of development, as well as in local and global leadership positions with full budgetary responsibility.

NorthX Biologics is a development and manufacturing company with expertise in the following areas Manufacturing of cell and gene therapies, proteins, vaccines and other advanced biologics. With two sites in Sweden and headquarters in Matfors, the team has been manufacturing biologics according to GMP standards since 1992.